Dicot Pharma AB (STO:DICOT)

Market Cap	432.81M -35.5%
Revenue (ttm)	n/a
Net Income	-72.14M
EPS	-0.04
Shares Out	2.01B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,242,780
Open	0.2160
Previous Close	0.2154
Day's Range	0.2066 - 0.2170
52-Week Range	0.1991 - 1.1800
Beta	0.91
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 30, 2026

About Dicot Pharma AB

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2015
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DICOT